Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the european organisation for research and treatment of cancer leukemia group and the German MDS study group

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 1987-1996

  Lübbert, Michael ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Suciu, Stefan ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Baila, Liliana ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Rüter, Björn Hans ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Platzbecker, Uwe ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Giagounidis, Aristoteles ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Selleslag, Dominik ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Labar, Boris ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Germing, Ulrich ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Salih, Helmut R ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Beeldens, Filip ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Muus, Petra ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Pflüger, Karl Heinz ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Coens, Corneel ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Hagemeijer, Anne ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Schaefer, Hans Eckart ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Ganser, Arnold ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Aul, Carlo ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   De Witte, Theo ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Wijermans, Pierre W ^{a,b,c,d,e,f,g,h,i,j,k,l,m}  

^a UNIVERSITY OF FREIBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c ST JOHANNES HOSPITAL   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^g Diakoniekrankenhaus Bremen   (Germany)

^h European Organisation for Research   (Belgium)

ⁱ General Hospital St Jan   (Belgium)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k KBC Zagreb   (Croatia)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m HAGA HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE DURATION; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC CARE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; HYPOPLASIA; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT REFUSAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79956294708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.9245     Document Type: Article

References (25)

1. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer: A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116, 2006
2. Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463, 2004 (Pubitemid 38715140)
3. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
4. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
5. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-1124, 2007 (Pubitemid 46435390)
6. Hellström-Lindberg E, Robèrt KH, Gahrton G, et al: A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol 81:503-511, 1992
7. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964, 2002
8. Fandy TE, Herman JG, Kerns P, et al: Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764-2773, 2009
9. Gore SD, Baylin S, Sugar E, et al: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369, 2006
10. Miller KB, Kim K, Morrison FS, et al: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III inter-group study. Ann Hematol 65:162-168, 1992
11. Wijermans P, Lübbert M, Verhoef G, et al: Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000 (Pubitemid 30123770)
12. Wijermans PW, Lübbert M, Verhoef G, et al: An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84:9-17, 2005 (suppl 1)
13. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
14. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
15. Kalbfleisch JD, Prentice RL: The Survival Analysis of Failure Time Data (ed 2). Hoboken, NJ, Wiley Inter-Science, 2002
16. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007 (Pubitemid 46053042)
17. Wijermans PW, Krulder JW, Huijgens PC, et al: Continuous infusion of low-dose 5-aza-2′- deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1-5, 1997 (Pubitemid 27065040)
18. Kornblith AB, Herndon JE 2nd, Silverman LR, et al: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 20: 2441-2452, 2002 (Pubitemid 34525729)
19. Deschler B, de Witte T, Mertelsmann R, et al: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 91:1513-1522, 2006 (Pubitemid 44736118)
20. Raj K, John A, Ho A, et al: CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937-1944, 2007
21. Flotho C, Claus R, Batz C, et al: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23:1019-1028, 2009
22. Kantarjian HM, O'Brien S, Shan J, et al: Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109: 265-273, 2007 (Pubitemid 46106241)
23. Estey E, Thall P, Beran M, et al: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90:2969-2977, 1997 (Pubitemid 27444190)
24. Silverman LR, Holland JF, Weinberg RS, et al: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7:21-29, 1993 (suppl 1) (Pubitemid 23184796)
25. Steensma DP, Baer MR, Slack JL, et al: Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) trial. J Clin Oncol 27: 3842-3848, 2009